In this issue:
NAFLD may be a modifiable risk factor for young-onset ovarian cancer
SOLO3: OS results for olaparib vs nonplatinum chemo for relapsed disease
Risk factors for anastomotic leakage
Final survival data from the NOVA niraparib maintenance trial
Real-world effectiveness of MIRV
Bevacizumab re-treatment beneficial after EOC progression
Better survival with interval vs delayed cytoreduction in advanced disease
Prognosis of subtypes of stage I ovarian mucinous tumours
Is primary vs interval cytoreductive surgery better for metastatic disease?
HIPEC at upfront surgery improves longterm survival in Stage 3 EOC
Please login below to download this issue (PDF)